Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Q3 FY2024 Earnings Presentation
16 slides from Little Green Pharma's earnings presentation, Apr 29, 2024
Slide 1: Investor webinar ASX announcement
ASX ASXANNOUNCEMENT ANNOUNCEMENT 29 APRIL 2024 Investor webinar For personal use only • Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to make available a recording of an investor webinar delivered by LGP’s Chief Executive Officer, Paul Long • The webinar provides an update on
Slide 2: Contact details and About Little Green Pharma
For further information please contact: Alistair Warren Paul Long David Tasker / Colin Jacoby Company Secretary Chief Executive Officer Chapter One Advisors Little Green Pharma Little Green Pharma E: dtasker@chapteroneadvisors.com.au E: a.warren@lgp.global E: p.long@lgp.global / cjacoby@chapteronead
Slide 3: March 2024 Quarterly & Appendix 4C
March 2024 Quarterly & Appendix 4C For personal use only ASX:LGP Investor presentation April 2024 The most trusted medicinal cannabis brand Little Green Pharma Quarterly Activities Report and Appendix 4C
Slide 4: Disclaimer
Disclaimer Disclaimer Not financial product advice For personal use only This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, taxation
Slide 5: Agenda
AGENDA Agenda For personal use only Highlights • Summary of Quarterly highlights Financial performance • Record revenue and cash receipts • Positive operating cashflow • Strong net tangible asset position Updates • New products • France • Germany, Poland, UK & Switzerland • Global Cannabis Wrap • Re
Slide 6: Quarterly highlights
QUARTERLY HIGHLIGHTS Quarterly highlights For personal use only HIGHLIGHTS Excellent quarter with record revenues and cash receipts and achievement of long-held goal of positive operating cashflow for quarter and financial year Company operating cashflow positive for the month of March without R&D r
Slide 7: Record revenue & cash receipts lead to positive operating cashflow
FINANCIAL HIGHLIGHTS Record revenue1 & cash receipts lead to positive operating cashflow For personal use only MARCH QUARTER REVENUE FY24 REVENUE Quarterly revenue & cash receipts (000’s) $7.3M $25.6M 9,000 8,000 8,100 ~35% on previous quarter ~30% on previous financial 6,675 5,436 year 7,000 MARCH
Slide 8: Positive net cashflows for FY2024
FINANCIAL HIGHLIGHTS Positive net cashflows for FY2024 Quarterly net operating cash inflows were $4.1 million, up from previous quarter net operating cash outflow of $1.8 million For personal use only • • Significant increase in cash receipts through March quarter, with LGP receiving its $5.0 millio
Slide 9: EV, NTA, cash, debt & financial year revenue
FINANCIAL HIGHLIGHTS EV, NTA, cash, debt & For personal use only financial year revenue EV, NTA, cash, debt & financial year revenue (000’s) • Net tangible assets continue to be significantly above the Company’s enterprise value 100,000 30,000 • Company’s asset base includes its Danish Facility, the
Slide 10: Product updates
NEW PRODUCTS Product updates For personal use only • The CherryCo Little Buddies range comprises six flowers featuring smaller Summer Sun flowers from high-quality batches but a lower price point and in a larger (15g) bag LGP launched its high THC Sativa dominant • The CherryCo Signature range compr
Slide 11: European update: France
EUROPEAN UPDATE France For personal use only • LGP and one other company now the sole suppliers to French patients during the nine-month post-trial transitional period • LGP preparing marketing authorisation applications for a range of cannabis products for post-transitional period • French cannabis
Slide 12: European update: Germany, Poland, UK & Switzerland
EUROPEAN UPDATE For personal use only Germany Poland • On 1 April 2024, Germany removed cannabis from the • LGP supplied its first shipment of Desert Flame Narcotics List flower to its Polish distribution partner, Medezin, with the product being well received in market • This is probably the single
Slide 13: Reset Mind Sciences update
RESET MIND SCIENCES For personal use only update • In February, Reset Mind Sciences withdrew its offer under its Prospectus following AIM decision that UK funds cannot invest in Reset given its Psychedelic Assisted Psychotherapy (PAP) activities and that Reset is not currently capable of listing on
Slide 14: LGP Global Cannabis Wrap
INVESTOR RELATIONS LGP Global Cannabis Wrap For personal use only • In April, LGP released its inaugural LGP Global Cannabis Wrap providing LGP shareholders and investors with insights on regulatory and other key developments in global cannabis markets • Investors interested in receiving the inaugur
Slide 15: Corporate Overview
INVESTOR RELATIONS Corporate Overview Capital Structure Shareholder Structure For personal use only Current Share Price1 $0.14 Shares Outstanding1 ~302 million 22% Options and Performance Rights on Issue2 ~42.9 million 29% Market Capitalisation (undiluted) ~$42.3 million Cash Reserves (31 March 2024
Slide 16: Thank you
For personal use only Thank you E6
Little Green Pharma — Q3 FY2024 Earnings Presentation on 6ix